| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Division of Clinical Immunology and Rheumatology, Department of Medicine and
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294; and
Department of Molecular Biology, DNAX Research Institute, Palo Alto, CA 94304
In vitro, IL-6 is the main inducer of the human C-reactive protein (CRP) gene, and IL-1 and steroids can enhance this effect. However, in mice, IL-6 is necessary but not sufficient for induction of the human CRP transgene, and testosterone is required for its constitutive expression by males. To examine the relative contributions of testosterone and IL-6 in the regulation of CRP gene expression, we produced CRP-transgenic (CRPtg), IL-6-deficient (IL-6-/-) mice. Male CRPtg/IL-6-/- mice expressed CRP constitutively, but CRP levels were not increased after injection of LPS. However, acute-phase CRP levels were attained after injection of IL-6. In contrast, female CRPtg/IL-6-/- mice did not express CRP constitutively or after administration of LPS, IL-6, IL-1, or IL-6 plus IL-1. Like males, testosterone-treated CRPtg/IL-6-/- females expressed CRP constitutively, and their transgene responded to injection of IL-6. The endogenous acute-phase protein serum amyloid P (SAP) was expressed constitutively equally by male and female IL-6-/- mice, responded minimally to LPS, and did not respond to either IL-6 or IL-1 alone. Acute-phase levels of SAP were induced in IL-6-/- mice by injection of IL-6 together with IL-1 or LPS. We conclude that in vivo, both constitutive and IL-6-dependent acute-phase expression of the CRP transgene require testosterone. In contrast, testosterone is not required for expression of the SAP gene, which requires IL-1 plus IL-6 for acute-phase induction.
This article has been cited by other articles:
|
|
 |
|
  F. G. Hage and A. J. Szalai C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, S. Oparil, Y.-F. Chen, M. A. McCrory, G. A. Skibinski, W. Feng, and A. J. Szalai Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2094 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Reifenberg, H.-A. Lehr, D. Baskal, E. Wiese, S. C. Schaefer, S. Black, D. Samols, M. Torzewski, K. J. Lackner, M. Husmann, et al. Role of C-Reactive Protein in Atherogenesis: Can the Apolipoprotein E Knockout Mouse Provide the Answer? Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Trion, M.P.M. de Maat, J.W. Jukema, A. van der Laarse, M.C. Maas, E.H. Offerman, L.M. Havekes, A.J. Szalai, H.M.G. Princen, and J.J. Emeis No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1635 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Hirschfield, J. R. Gallimore, M. C. Kahan, W. L. Hutchinson, C. A. Sabin, G. M. Benson, A. P. Dhillon, G. A. Tennent, and M. B. Pepys Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice PNAS, June 7, 2005; 102(23): 8309 - 8314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kovacs, P. Henriksson, A. Hamsten, H. Wallen, J. Bjorkegren, and P. Tornvall Hormonal Regulation of Circulating C-Reactive Protein in Men Clin. Chem., May 1, 2005; 51(5): 911 - 913. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Motomura, H. Kanbayashi, W. I. Khan, Y. Deng, P. A. Blennerhassett, P. J. Margetts, J. Gauldie, K. Egashira, and S. M. Collins The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-{beta} type II receptor gene transfer Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G143 - G150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Burke, A. Pridmore, N. Harraghy, A. Collick, J. Brown, and T. Mitchell Transgenic Mice Showing Inflammation-Inducible Overexpression of Granulocyte Macrophage Colony-Stimulating Factor Clin. Vaccine Immunol., May 1, 2004; 11(3): 588 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Hirschfield, J. Herbert, M. C. Kahan, and M. B. Pepys Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice J. Immunol., December 1, 2003; 171(11): 6046 - 6051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. N. Das Is Metabolic Syndrome X an Inflammatory Condition? Experimental Biology and Medicine, December 1, 2002; 227(11): 989 - 997. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.-M. Fernandez-Real, M. Pugeat, M. Grasa, M. Broch, J. Vendrell, J. Brun, and W. Ricart Serum Corticosteroid-Binding Globulin Concentration and Insulin Resistance Syndrome: A Population Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4686 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Garnero, C. Jamin, C.-L. Benhamou, C. Pelissier, and C. Roux Effects of tibolone and combined 17{beta}-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial Hum. Reprod., October 1, 2002; 17(10): 2748 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Szalai, S. Nataf, X.-Z. Hu, and S. R. Barnum Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein J. Immunol., June 1, 2002; 168(11): 5792 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Singh, S. Hsia, P. Alaupovic, I. Sinha-Hikim, L. Woodhouse, T. A. Buchanan, R. Shen, R. Bross, N. Berman, and S. Bhasin The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 136 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Fernandez-Real, M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Vendrell, and W. Ricart Circulating Interleukin 6 Levels, Blood Pressure, and Insulin Sensitivity in Apparently Healthy Men and Women J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1154 - 1159. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. J. Szalai, J. L. VanCott, J. R. McGhee, J. E. Volanakis, and W. H. Benjamin Jr. Human C-Reactive Protein Is Protective against Fatal Salmonella enterica Serovar Typhimurium Infection in Transgenic Mice Infect. Immun., October 1, 2000; 68(10): 5652 - 5656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Szalai, F. W. van Ginkel, Y. Wang, J. R. McGhee, and J. E. Volanakis Complement-Dependent Acute-Phase Expression of C-Reactive Protein and Serum Amyloid P-Component J. Immunol., July 15, 2000; 165(2): 1030 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Jones, D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, and G. M. Fuller C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding J. Exp. Med., February 1, 1999; 189(3): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
